Protein Engineering vol. 16 no. 12 pp. 1081-1087, 2003
© 2003 Oxford University Press
Interleukin-2 mutants with enhanced
-receptor subunit binding affinity
1Department of Chemical Engineering and Biological Engineering Division, Massachusetts Institute of Technology, MIT 66-552, Cambridge, MA 02139 and 2Dartmouth Medical School, Hanover, NH 03755, USA
3 To whom correspondence should be addressed. e-mail: wittrup{at}mit.edu
Stimulation of T-cells by IL-2 has been exploited for treatment of metastatic renal carcinoma and melanoma. However, a narrow therapeutic window delimited by negligible stimulation of T-cells at low picomolar concentrations and undesirable stimulation of NK cells at nanomolar concentrations hampers IL-2-based therapies. We hypothesized that increasing the affinity of IL-2 for IL-2R
may create a class of IL-2 mutants with increased biological potency as compared with wild-type IL-2. Towards this end, we have screened libraries of mutated IL-2 displayed on the surface of yeast and isolated mutants with a 1530-fold improved affinity for the IL-2R
subunit. These mutants do not exhibit appreciably altered bioactivity at 0.55 pM in steady-state bioassays, concentrations well below the IL-2R
equilibrium binding constant for both the mutant and wild-type IL-2. A mutant was serendipitously identified that exhibited somewhat improved potency, perhaps via altered endocytic trafficking mechanisms described previously.
Received June 13, 2003; revised July 30, 2003; accepted September 26, 2003
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C. D. Thanos, W. L. DeLano, and J. A. Wells Hot-spot mimicry of a cytokine receptor by a small molecule PNAS, October 17, 2006; 103(42): 15422 - 15427. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Colby, Y. Chu, J. P. Cassady, M. Duennwald, H. Zazulak, J. M. Webster, A. Messer, S. Lindquist, V. M. Ingram, and K. D. Wittrup Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody PNAS, December 21, 2004; 101(51): 17616 - 17621. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Rao, I. Driver, D. A. Lauffenburger, and K. D. Wittrup Interleukin 2 (IL-2) Variants Engineered for Increased IL-2 Receptor {alpha}-Subunit Affinity Exhibit Increased Potency Arising from a Cell Surface Ligand Reservoir Effect Mol. Pharmacol., October 1, 2004; 66(4): 864 - 869. [Abstract] [Full Text] [PDF] |
||||

